HeartSciences Inc. (NASDAQ:HSCS) Short Interest Up 115.9% in June

HeartSciences Inc. (NASDAQ:HSCS) was the recipient of a large increase in short interest in the month of June. As of June 30th, there was short interest totaling 123,640 shares, an increase of 115.9% from the June 15th total of 57,278 shares. Based on an average daily volume of 13,681,823 shares, the short-interest ratio is currently 0.0 days. Approximately 4.1% of the shares of the company are short sold.

HeartSciences Trading Down 3.8%

Shares of HSCS traded down $0.10 during trading hours on Wednesday, hitting $2.52. 16,778 shares of the stock traded hands, compared to its average volume of 1,082,361. The company has a current ratio of 1.19, a quick ratio of 1.04 and a debt-to-equity ratio of 0.16. HeartSciences has a 1-year low of $1.63 and a 1-year high of $4.30. The firm has a market capitalization of $8.01 million, a PE ratio of -0.51 and a beta of 1.78. The business has a fifty day moving average of $2.17 and a 200-day moving average of $2.52.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HeartSciences in a report on Wednesday, June 24th. Ascendiant Capital Markets cut their target price on HeartSciences from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, March 24th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, HeartSciences currently has a consensus rating of “Hold” and a consensus target price of $8.00.

Institutional Investors Weigh In On HeartSciences

A hedge fund recently bought a new stake in HeartSciences stock. Geode Capital Management LLC purchased a new stake in HeartSciences Inc. (NASDAQ:HSCS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned 0.51% of HeartSciences as of its most recent SEC filing. 17.24% of the stock is owned by institutional investors and hedge funds.

About HeartSciences

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non?invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high?fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high?frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.